Skip to main content

Table 1 Clinical characteristics of patients from whom CAFs were isolated. Data are presented separately for each analysis

From: Dual effect of vitamin D3 on breast cancer-associated fibroblasts

 

All patients

Menopausal status

Vitamin D3 level

Metastases

Premenopausal

Post-menopausal

Deficient

Normal

Absent

Present

 

n = 127

n = 38

n = 89

n = 89

n = 38

n = 96

n = 31

Age

60.6 ± 12.4

47.5 ± 8.6

66.3 ± 9.1*

61.8 ± 12.5

57.8 ± 11.9

60.4 ± 12.9

61.5 ± 11.01

Plasma 25(OH)D3 level [ng/ml]

25.6 ± 12.4

27.6 ± 9.6

24.7 ± 13.4

19.0 ± 6.3

41.0 ± 9.1#

25.6 ± 12.7

25.6 ± 11.9

Plasma FSH level [mIU/ml]

52.8 ± 35.0

14 ± 16.4

69.5 ± 26.6*

53.7 ± 32.6

50.8 ± 40.5

53.3 ± 37.1

51.1 ± 27.8

Selected protein levels in tumor tissue

n = 80

n = 28

n = 52

n = 57

n = 23

n = 53

n = 27

Age

60.2 ± 13.0

46.5 ± 6.6

67.6 ± 8.8*

60.4 ± 13.2

59.7 ± 12.7

59.6 ± 13.8

61.3 ± 11.4

Plasma 25(OH)D3 level [ng/ml]

24.4 ± 11.4

26.5 ± 9.4

23.3 ± 12.2

18.5 ± 6.1

39.0 ± 7.3#

24.2 ± 11.0

24.7 ± 12.3

Plasma FSH level [mIU/ml]

46.0 ± 33.2

12.6 ± 12.3

64.4 ± 25.8*

47.1 ± 31.3

43.5 ± 38.1

45.9 ± 36.2

46.3 ± 26.7

CAFs’ phenotype

n = 71

n = 28

n = 43

n = 51

n = 20

n = 52

n = 19

Age

58.9 ± 13.4

45.4 ± 7.4

67.7 ± 7.9*

60.4 ± 13.5

55.1 ± 12.7

58.1 ± 14.0

61.1 ± 11.5

Plasma 25(OH)D3 level [ng/ml]

25.5 ± 12.9

27.8 ± 9.9

24.1 ± 14.5

18.9 ± 6.2

42.4 ± 9.8#

27.1 ± 13.9

21.0 ± 8.4

Plasma FSH level [mIU/ml]

48.9 ± 36.5

12.6 ± 12.3

73.0 ± 25.3*

47.3 ± 31.0

52.8 ± 48.2

50.2 ± 39.7

45.0 ± 25.5

CAFs’ sensitivity to antiproliferative calcitriol activity

n = 36

n = 15

n = 21

n = 24

n = 12

n = 23

n = 13

Age

58.2 ± 12.6

46.6 ± 7.0

66.5 ± 8.3*

60.4 ± 12.4

53.8 ± 12.1

59.5 ± 14.2

55.9 ± 8.9

Plasma 25(OH)D3 level [ng/ml]

26.4 ± 11.4

28.4 ± 11.6

25 ± 11.3

19.6 ± 5.8

40.2 ± 5.6#

27.2 ± 12.7

25.1 ± 8.9

Plasma FSH level [mIU/ml]

47.6 ± 32.8

15.1 ± 14.1

71.9 ± 18.2*

52.4 ± 31.0

38.3 ± 35.7

47.2 ± 34.7

48.4 ± 30.5

Level of selected markers on calcitriol-treated CAFs

n = 51

n = 18

n = 33

n = 34

n = 17

n = 35

n = 16

Age

59.9 ± 13.6

45.2 ± 7.4

67.9 ± 8.5*

61.4 ± 14.1

56.9 ± 12.5

60.6 ± 15.0

59.5 ± 10.4

Plasma 25(OH)D3 level [ng/ml]

27.1 ± 13.2

27.8 ± 10.7

26.7 ± 14.5

19.5 ± 6.5

42.3 ± 9.3#

49.3 ± 34.5

51.2 ± 27.6

Plasma FSH level [mIU/ml]

49.9 ± 32.3

13.7 ± 13.3

70.3 ± 19.0*

49.2 ± 30.1

51.3 ± 37.1

28.1 ± 14.8

24.9 ± 8.7

mRNA expression in calcitriol-treated CAFs

n = 44

n = 15

n = 29

n = 29

n = 15

n = 29

n = 15

Age

59.8 ± 12.6

46.3 ± 6.9

66.8 ± 8.5*

62.4 ± 12.4

54.8 ± 11.7

60.4 ± 13.8

58.7 ± 10.2

Plasma 25(OH)D3 level [ng/ml]

27.6 ± 13.6

29.3 ± 11.0

26.7 ± 14.9

19.3 ± 5.9

43.6 ± 9.1#

29.3 ± 15.5

24.2 ± 8.7

Plasma FSH level [mIU/ml]

52.9 ± 31.9

15.4 ± 13.9

73.0 ± 16.8*

53.5 ± 28.3

51.7 ± 38.7

54.4 ± 33.9

49.8 ± 28.1

Protein expression in calcitriol-treated CAFs

n = 35

n = 12

n = 23

n = 21

n = 14

n = 21

n = 14

Age

59.7 ± 13.1

45.4 ± 7.3

67.2 ± 8.4*

62.4 ± 12.9

55.7 ± 12.9

59.4 ± 14.3

60.3 ± 11.1

Plasma 25(OH)D3 level [ng/ml]

28.4 ± 12.7

29.3 ± 12.3

27.9 ± 13.2

19.5 ± 6.1

41.9 ± 6.5#

30.0 ± 14.2

25.5 ± 9.3

Plasma FSH level [mIU/ml]

53.4 ± 32.9

14.2 ± 15.5

74.8 ± 14.9*

53.8 ± 29.2

52.8 ± 38.8

53.8 ± 34.6

52.6 ± 26.7

Protein concentration in cell supernatants from calcitriol-treated CAFs

n = 51

n = 18

n = 33

n = 34

n = 17

n = 35

n = 16

Age

59.9 ± 13.6

45.2 ± 7.4

67.9 ± 8.5*

61.4 ± 14.1

59.6 ± 12.5

60.1 ± 15.0

59.5 ± 10.4

Plasma 25(OH)D3 level [ng/ml]

27.1 ± 13.2

27.8 ± 10.7

26.7 ± 14.5

19.5 ± 6.5

42.3 ± 9.3#

28.1 ± 14.8

24.9 ± 8.7

Plasma FSH level [mIU/ml]

49.9 ± 32.3

13.7 ± 13.3

70.3 ± 19.0*

49.2 ± 30.1

51.3 ± 37.1

49.3 ± 34.5

51.2 ± 28.6

Gelatinases activity in calcitriol-treated CAFs

n = 16

n = 10

n = 6

n = 9

n = 7

n = 10

n = 6

Age

54.8 ± 12.7

46.6 ± 6.9

68.3 ± 6.6*

58.11 ± 9.6

50.4 ± 15.6

50.7 ± 13.6

61.5 ± 8.1

Plasma 25(OH)D3 level [ng/ml]

29.3 ± 12.2

31.3 ± 12.8

26.0 ± 11.5

20.0 ± 6.9

41.2 ± 3.8#

31.1 ± 13.1

26.3 ± 11.2

Plasma FSH level [mIU/ml]

34.2 ± 32.4

14.9 ± 15.6

72.7 ± 18.4*

41.3 ± 27.2

26.0 ± 38.0

28.8 ± 34.7

42.2 ± 29.7

Calcitriol-treated CAFs’ impact on breast cancer cells

n = 16

n = 7

n = 9

n = 10

n = 6

n = 9

n = 7

Age

60.7 ± 11.7

49.1 ± 5.0

69.7 ± 5.6*

59.5 ± 10.1

62.7 ± 14.9

59.9 ± 14.0

63.0 ± 8.4

Plasma 25(OH)D3 level [ng/ml]

26.9 ± 10.4

26.4 ± 12.3

27.2 ± 9.5

20.4 ± 6.6

37.6 ± 5.1#

26.6 ± 11.0

27.3 ± 10.5

Plasma FSH level [mIU/ml]

45.4 ± 32.2

19.1 ± 17.1

68.4 ± 22.9*

46.5 ± 29.9

43.8 ± 38.4

40.5 ± 36.6

52.7 ± 25.7

  1. Patients were classified into groups according to plasma 25(OH)D3 levels (< 30 ng/mL—deficient, > 30 ng/mL—normal), plasma FSH levels (< 25.8 mIU/mL—premenopausal, > 25.8 mIU/mL—postmenopausal) and the presence of regional or distant metastases (if any—present, otherwise absent). Data are presented as the mean ± SD. Statistical analysis was carried out using Student’s t-test or the Mann‒Whitney U test: *p < 0.05—premenopausal vs postmenopausal, #p < 0.05—normal vs deficient vitamin D3 level
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us